Population implications of lipid lowering for prevention of coronary heart disease: Data from the 1995 Scottish health survey

Heart

Volumn 86, Issue 3, 2001, Pages 289-295

  Haq, I U ^a   Ramsay, L E ^a   Wallis, E J ^a   Isles, C G ^b   Ritchie, L D ^c   Jackson, P R ^a  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^b DUMFRIES AND GALLOWAY ROYAL INFIRMARY   (United Kingdom)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Coronary risk; Primary prevention; Secondary prevention; Statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEALTH CARE POLICY; HEALTH SURVEY; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECONDARY PREVENTION; UNITED KINGDOM;

EID: 0034877204     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/heart.86.3.289     Document Type: Article

References (21)

1. Randomised trial of cholesterol lowering in 4444 patients with CHD: The Scandinavian simvastatin survival study (4S)
2. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
3. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad of initial cholesterol levels
4. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia
5. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels
6. An evidence based approach to individualising patient treatment
7. Lipid-lowering for prevention of coronary heart disease: What policy now?
8. The Sheffield table for primary prevention of coronary heart disease: Corrected
9. The number needed to treat: A clinically useful measure of treatment effect
10. Cost-effectiveness of HMG CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment
11. Joint British recommendations on prevention of coronary heart disease in clinical practice
12. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other societies on coronary prevention
13. Prediction of coronary risk for primary prevention of coronary heart disease: A comparison of methods
14. Indication for cholesterol-lowering medication: Comparison of risk-assessment methods
15. Cardiovascular disease risk profiles
16. Dietary reduction if serum cholesterol concentration: Time to think again
17. Systematic review of dietary intervention trials to lower blood total cholesterol in free-living subjects
18. Systematic review of randomised controlled trials of multiple risk factor interventions for preventing coronary heart disease